(MENAFN- GlobeNewsWire - Nasdaq) The pharma sector in Q3 2025 presents opportunities in oncology, highlighted by its prominence in M&A deals despite a drop in overall deal volume. The surge in deal value indicates robust interest and potential for strategic investments, especially in biopharmaceutical innovations.

Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The "M&A Trends in Pharma - Q3 2025" report has been added to ResearchAndMarkets's offering.
This report analyzes the merger and acquisition (M&A) activity in Q3 2025 in the Pharma sector.
The global pharma sector in Q3 2025 saw a surge in deal value, with $43.2 billion worth of deals, representing an increase of 36.7% compared to Q2 deal volume, declined by 21.9% to 107 M&A deals in Q3 2025. Oncology emerged as the leading therapeutic area recording 32 deals.
Scope

• This report provides an overview of M&A activity globally in Q3 2025 in the Pharma sector involving biopharmaceutical drug companies.
• It identifies key trends, and the most notable deals announced in Q3 2025 in the Pharma sector.

Reasons to Buy

• Companies that make strategic investments in M&A position themselves for success, while those that fail to adapt risk falling behind.
• This report provides an overview of global M&A trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.

Key Topics Covered:
1 Table of Contents
2 Pharma M&A Activity in Q3 2025
3 Global M&A Trends in Pharma
4 Global Quarterly M&A Activity in Pharma
5 Ownership Type: Private Vs Public (Count)
6 Ownership Type: Private Vs Public (Value)
7 Global M&A Activity in Pharma by Deal Size
8 Notable Pharma Deals in Q3 2025
9 Pharma Regional Comparison - Q3 2025
10 Global Cross Border M&A Trends in Pharma
11 Inbound and Outbound Deals in Pharma in Q3 2025
12 Regional M&A Activity in Pharma by Value and Volume
13 Pharma M&A Review by Top 10 Countries
14 Top 10 Therapy Area M&A Review
15 Further Information
Companies Featured

• Merck & Co
• Verona Pharma
• Genmab
• Merus
• Pfizer
• Metsera
• F. Hoffmann-La Roche
• 89bio
• Innosera
• Bavarian Nordic
• Sanofi
• Vicebio
• Novartis
• Tourmaline Bio
• Sino Biopharmaceutical
• LaNova Medicines
• Bausch Health Companies
• DURECT
• Serb SAS
• Y-mAbs Therapeutics

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN11112025004107003653ID1110328035